Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma

Gut

Volumn 66, Issue 2, 2017, Pages 342-351

  Garnelo, Marta ^a   Tan, Alex ^a   Her, Zhisheng ^b   Yeong, Joe ^a,c   Lim, Chun Jye ^a   Chen, Jinmiao ^a   Lim, Kiat Hon ^c   Weber, Achim ^d   Chow, Pierce ^c,e,k   Chung, Alexander ^c,e   Ooi, London Lucien P J ^c,e,k   Toh, Han Chong ^e   Heikenwalder, Mathias ^f,g   Ng, Irene O L ^h,i   Nardin, Alessandra ^a   Chen, Qingfeng ^b,e   Abastado, Jean Pierre ^a,j   Chew, Valerie ^a,k  

^a Singapore Health Services   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ THE UNIVERSITY OF HONG KONG   (Hong Kong)

^j IRIS Institut de Recherches Internationales Servier   (France)

^k DUKE NUS MEDICAL SCHOOL   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD8ALPHA ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; GRANZYME B; KI 67 ANTIGEN; TUMOR MARKER; CD20 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CD8 ANTIGEN, ALPHA CHAIN; GRANZYME; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DENSITY; CELL INTERACTION; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DEPLETION; FEMALE; FLOW CYTOMETRY; HEPATOMA CELL; HONG KONG; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SINGAPORE; SWITZERLAND; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE DEPLETION; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD27; ANTIGENS, CD3; ANTIGENS, CD38; ANTIGENS, CD40; ANTIGENS, CD8; B-LYMPHOCYTES; CARCINOMA, HEPATOCELLULAR; CASPASE 3; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GRANZYMES; HUMANS; INTERFERON-GAMMA; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 85011392068     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310814     Document Type: Article

References (40)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res 2013;19:2810-16.
3. Pagès F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-102.
4. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 2011;236:567-79.
5. Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012;61:1733-43.
6. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol 2013;34:169-73.
7. Shao Y, Lo CM, Ling CC, et al. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway. Cancer Lett 2014;355:264-72.
8. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126-44.
9. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009;157:9-19.
10. Pauken KE, Wherry EJ. TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit. Cancer Cell 2014;26:785-7.
11. Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012;61:427-38.
12. Abel EJ, Bauman TM, Weiker M, et al. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Hum Pathol 2014;45:1092-9.
13. Stack EC, Wang C, Roman KA, et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 2014;70:46-58.
14. Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 2015;21:998-1009.
15. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010;52:370-9.
16. Montalvao F, Garcia Z, Celli S, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013;123:5098-103.
17. Kobata T, Jacquot S, Kozlowski S, et al. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA 1995;92:11249-53.
18. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17:275-81.
19. Hernandez MG, Shen L, Rock KL. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help. J Immunol 2007;178:2844-52.
20. Kaminski DA, Wei C, Qian Y, et al. Advances in human B cell phenotypic profiling. Front Immunol 2012;3:302.
21. Mallone R, Funaro A, Zubiaur M, et al. Signaling through CD38 induces NK cell activation. Int Immunol 2001;13:397-409.
22. Sandoval-Montes C, Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J Leukoc Biol 2005;77:513-21.
23. Musso T, Deaglio S, Franco L, et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001;69:605-12.
24. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977-82.
25. Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012;18:3281-92.
26. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol 2011;89:195-203.
27. He L-Z, Prostak N, Thomas LJ, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013;191:4174-83.
28. Roberts DJ, Franklin NA, Kingeter LM, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010;33:769-79.
29. Nolte MA, van Olffen RW, van Gisbergen KP, et al. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009;229:216-31.
30. Wherry EJ, Teichgräber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8T cell subsets. Nat Immunol 2003;4:225-34.
31. Wei C, Jung J, Sanz I. OMIP-003: phenotypic analysis of human memory B cells. Cytometry A 2011;79:894-6.
32. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol 2015;15:149-59.
33. Wang XD, Wang L, Ji FJ, et al. Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma. J Int Med Res 2012;40:307-16.
34. Pittner BT, Shanafelt TD, Kay NE, et al. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005;19:2264-72.
35. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunological reviews 1996;153:85-106.
36. Khong A, Nelson DJ, Nowak AK, et al. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 2012;31:246-66.
37. Fuertes Marraco SA, Neubert NJ, Verdeil G, et al. Inhibitory receptors beyond T cell exhaustion. Front Immunol 2015;6:310.
38. Zhang S, Zhang H, Zhao J. The role of CD4T cell help for CD8 CTL activation. Biochem Biophys Res Commun 2009;384:405-8.
39. Phares TW, Stohlman SA, Hwang M, et al. CD4T cells promote CD8T cell immunity at the priming and effector site during viral encephalitis. J Virol 2012;86: 2416-27.
40. Castiglioni P, Gerloni M, Cortez-Gonzalez X, et al. CD8T cell priming by B lymphocytes is CD4 help dependent. Eur J Immunol 2005;35:1360-70.